Tagged with Generics

Portugal A doyen of Portuguese pharma, Pedro Ferraz da Costa is the long-serving president of the company started by his parents, Iberfar. In conversation with PharmaBoardroom, he discusses how Iberfar’s business has evolved in recent years, the direction of travel his country should take to safeguard its homegrown industry and the…

India The Indian pharma industry has demonstrated spectacular growth based on its strength as a global generics manufacturer. Yet Indian pharma is not merely resting on its laurels. After shining through the COVID-19 pandemic and despite recent quality issues, the country’s pharmaceutical sector is looking to refocus its efforts on innovation…

Portugal Last year, Tecnimede Group – a family-owned titan of the Portuguese healthcare industry – appointed its first professional, non-family CEO in Antonio Donato. This marked a significant milestone in the company’s professionalisation and its journey towards becoming an international, multinational entity. In conversation, Donato outlines Tecnimede’s current internationalisation strategy and…

India Peter DeYoung shares the significance of Indian giant Piramal Pharma’s recent demerger from its parent company and its current strategic focus on organic growth, brownfield expansions, and “complex hospital generics.” DeYoung also touches on what brought him from the world of consulting and private equity to a family-owned Indian pharma…

Portugal Erstwhile 21-year CEO of leading Portuguese generics group Tecnimede, Maria do Carmo Neves today serves as president of her country’s generics industry association, APOGEN. She outlines the highly challenging market situation facing generics, biosimilar, and value-added medicine producers in Portugal today; how this situation reflects Europe-wide trends; and the solutions…

India As secretary general of the Indian Pharmaceutical Alliance (IPA) Sudarshan Jain represents the interests of 25 leading Indian pharmaceutical companies, both at home and abroad. He outlines the association’s focus on quality, innovation, and global reach, why the IPA is aiming to position India as a global benchmark for pharma…

UAE Drawing on a quarter of a century of pharmaceutical industry experience, over 20 years of which has been spent in the UAE, Ayman Mokhtar today heads up Middle East, North Africa and Eurasia operations for Viatris. A global healthcare company with a broad range of products, Viatris is continually working…

Morocco Cooper Pharma is one of Morocco’s leading domestic pharmaceutical manufacturers and has expanded its presence across Europe, the Middle East, and Africa in recent years. CEO Ayman Cheikh Lahlou emphasizes the importance of healthcare investment for a developing nation, highlighting Morocco’s commitment to self-sufficiency in pharmaceuticals, the potential for Morocco…

Morocco Zenith Pharma’s Mohamed El Bouhmadi discusses the company’s approach to product development and the potential for Morocco to become an African pharmaceutical export platform. As Morocco transitions to universal healthcare coverage, he highlights the need for balanced medication pricing. With a robust growth trajectory and a focus on high-value products,…

Switzerland As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment Humira, the newly spun-off company has been gearing up for its independence by preparing additional biosimilar launches, signing big partnership…

Morocco Salim El Guermaï of leading Moroccan generics manufacturer Galenica outlines how, in the past three years, the firm played a key role in Morocco’s COVID-19 pandemic response, continued to serve Moroccan patients with essential medicines, and bolstered the country’s standing as a pharmaceutical hub for the African continent.    Our…

Morocco Three years on from his last PharmaBoardroom interview, Karim Lahlou highlights the evolution of Moroccan pharma manufacturer Iberma as it expands its activities from solely in-licensing to developing and selling its own products, growing its global partnership base, and looking to penetrate international markets while leveraging the growing reputation of…